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Past
The peritoneum is a potential site of metastasis in virtually all pelvic and 
abdominal malignancies. Surgical treatment with debulking or complete 
cytoreduction with or without hyperthermic intraperitoneal chemotherapy 
(HIPEC) can provide palliation of symptoms and potentially, survival 
advantages over other treatments. However, radiographic identification of 
residual or recurrent peritoneal disease is challenging.1,2 A biomarker which 
could identify residual or recurrent disease might provide improved 
postoperative risk stratification and surveillance assessments. Cell-free 
circulating tumor DNA (ctDNA) shed from tumor is measurable in plasma and
provides both quantitative and qualitative data that can be assessed non-
invasively over time. We have previously found that ctDNA liquid biopsy is a 
preoperative prognosticator after surgical resection of peritoneal 
metastases,3 but questions remain about its utility for risk stratification and 
surveillance in the postoperative setting.
Present
As demonstrated in our study,4 there are specific postoperative ctDNA 
findings that have clear implications for progression and prognosis, such as 
development of a new clonal population (i.e. the detection of new alterations
by ctDNA, distinct from the prior detected mutational profile). However, the 
detection of early postoperative ctDNA is not an independent predictor of 
worse progression-free survival, in our somewhat limited cohort. Additionally,
it appears that the peritoneum may be relatively sequestered with regards to
systemic blood ctDNA detection: tumors types with a low rate of detection 
preoperatively have a much higher rate of detection postoperatively, despite
having well-characterized mutations that would be detectable in plasma. 
Future
While ctDNA sequencing has shown promise for surveillance after definitive 
local therapies in other contexts,5 its implementation in metastatic disease to
the peritoneum may require a more nuanced approach. Our findings suggest
that detection of ctDNA is the sum of numerous effects; some known (e.g. 
surgical removal of locoregional disease, a fixed gene panel), some 
suspected (e.g. a blood-peritoneal ctDNA barrier), and likely many more 
unknown. Questions of chronicity appear to be critical to implementation of 
these assays after surgery for peritoneal metastases. What is the ideal delay 
after surgery to assess ctDNA response? What is the effect of intraoperative 
chemotherapy? Does the observed blood-peritoneal barrier recover 
postoperatively, and if so, over what time? Should ctDNA be followed 
longitudinally? A larger clinical trial of serial ctDNA analysis in patients 
undergoing resection of peritoneal metastases is the obvious next step to 
translate this technology into clinical utility.
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